EUCTR2007-004120-21-ES
Active, not recruiting
Not Applicable
Ensayo clínico en fase 3 para evaluar la seguridad y la eficacia del tratamiento con 2 mg de Allovectin-7® intralesional comparado con dacarbazina (DTIC) o temozolomida (TMZ) en pacientes con melanoma recurrente metastásico - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)
Vical Incorporated0 sites375 target enrollmentNovember 21, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Recurrent metastatic melanoma
- Sponsor
- Vical Incorporated
- Enrollment
- 375
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Able and willing to provide informed consent and sign the informed consent form
- •\- Age 18 or more years
- •\- ECOG performance status of 0 or 1
- •\- Histologically confirmed recurrent metastatic melanoma, which may have received primary surgical resection, adjuvant therapy, and/or biotherapy
- •\- At least one injectable lesion (cutaneous, subcutaneous, or nodal lesion) \=1 cm2 and \=25 cm2\. Lesions between 25 cm2 and 100 cm2 are not injected but may be followed as target lesions
- •\- LDH within normal limits
- •\- Serum creatinine \= 2\.0 mg/dL
- •\- Platelet count 100,000/mm3 or more
- •\- White blood cell count 2500/mm3 or more
- •\- Male and female subjects of child bearing potential must agree to use an effective method of contraception
Exclusion Criteria
- •\- Prior cytotoxic chemotherapy for malignant melanoma
- •\- Prior Allovectin\-7® injection(s)
- •\- Any lesion 100 cm2 or more
- •\- History of visceral metastasis, M1c, other than lung (M1b not excluded)
- •\- Surgery as a curative option
- •\- Radiation therapy, immunosuppressive therapy or biologic therapy within four weeks prior to trial entry
- •\- Major surgery within two weeks prior to trial entry
- •\- Known positive HIV serology
- •\- Other malignancy not currently in remission or unlikely to have been cured with prior therapy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or low grade prostate cancer)
- •\- Concurrent immunosuppressive therapy, anticancer therapy or investigational treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Ensayo clínico, fase III, para conocer la seguridad y eficacia de Sativex® para el alivio sintomático de la espasticidad en sujetos con esclerosis múltiple (Fase A Simple ciego para conocer la respuesta, y fase B, doble ciego, aleatorizado, con grupos paralelos controlado con placeboEspasticidad en esclerosis múltipleEUCTR2006-005910-11-ESGW Pharma Ltd.356
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-ITMERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.700
Completed
Phase 3
Safety and Immunogenicity of V116 in Vaccine-Experienced AdultsPneumococcal infection preventionJPRN-jRCT2071220025Tanaka Yoshiyuki63
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsPneumococcal diseaseMedDRA version: 20.0Level: LLTClassification code 10035644Term: Pneumococcal infection NOSSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2021-006679-41-ESMerck Sharp & Dohme LLC700
Active, not recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Vaccine-Experienced AdultsEUCTR2021-006679-41-FRMerck Sharp & Dohme LLC717